- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. The NICE-Wide Prioritisation Board met 04 August 2025 and concluded that the clear rationale to not evaluate this product is due to many other oral iron preparations being already available for iron deficiency anaemia in chronic kidney disease. In addition, it was acknowledged that although ferric citrate’s dual effect has been demonstrated in clinical studies. Phosphate management in CKD is currently addressed using existing low-cost generic treatments. In light of this, the Prioritisation Board concluded that ferric citrate does not meet a significant unmet need or offer added value over current options sufficient to warrant selection for technology appraisal. Therefore, there would be no additional value in conducting an evaluation for ferric citrate. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12221
Email enquiries
If you have any queries please email [email protected]
Related links
For further information on how we select topics for development, please see our page about prioritising our guidance topics